Supported in part by the Japan Society for the Promotion of Science, Tokyo, Japan (Grant-in-Aid for Scientific Research no. 96005260), and Novartis Pharma K.K., Tokyo, Japan. No additional external funding was received for this study. The sponsors or funding organizations had no role in the design or conduct of this research.
Author contributions: Conception and design of the study (YM); analysis and interpretation (TK, YM, YI, SN); writing of the article (TK, YM, YI); critical revision of the article (SO, TM, SK, YI-M, SN, MM, MM, AU, AT); final approval of the article (TK, YM, YI, SO, TM, SK, YI-M, SN, MM, MM, AU, AT); data collection (TK, YM, YI, SO, TM).
Disclosure: T. Kogo, None; Y. Muraoka, Bayer (F), Novartis Pharma K.K. (F), Senju (F), Canon (F), and Nidek (F); Y. Iida, None; S. Ooto, Novartis Pharma K.K. (F), Bayer (F), Santen (F), and Senju (F); T. Murakami, Bayer (F), Novartis Pharma K.K. (F), Santen (F), and Senju (F); S. Kadomoto, None; Y. Iida-Miwa, None; S. Numa, None; M. Miyake, None; M. Miyata, None; A. Uji, Bayer (F), Novartis Pharma K.K. (F), Senju (F), Canon (F), and Nidek (F); A. Tsujikawa, Pfizer (F), Novartis Pharma K.K. (F), Bayer (F), Alcon (F), Santen (F), Senju (F), Nidek (F), and AMO Japan (F)